

LETTER

Arg¹⁸⁰⁹ substitution in neurofibromin: further evidence of a genotype–phenotype correlation in neurofibromatosis type 1

European Journal of Human Genetics (2015) 23, 1460–1461; doi:10.1038/ejhg.2015.93; published online 13 May 2015

Pinna *et al* recently proposed a novel genotype–phenotype correlation in neurofibromatosis type 1 (NF1; MIM 162200).¹ They reported six unrelated patients with the heterozygous c.5425C>T p.(Arg1809Cys) missense variant that causes a mild form of NF1, characterized by café-au-lait spots (CALs) and skinfold freckling (SF) without other typical signs of the condition such as Lisch nodules (LNs) and neurofibromas (NFs). Short stature, macrocephaly, thoracic anomalies, and other Noonan syndrome (NS) features were also present. Conversely, typical NF1-related tumors (eg, optic gliomas, plexiform NF) and congenital heart defects were not observed.¹

After the cloning of *NF1*,² several studies explored the NF1 phenotype to define any genotype–phenotype correlation. In the past three decades, only two scenarios have been described: the c.2970_2972delAAT p.(Met992del) in-frame deletion and the *NF1* microdeletion, related to a benign and a very severe NF1 phenotype,^{3–5} respectively. No other noteworthy correlations have been reported in NF1, although significant intrafamilial correlations for number of CALs, cutaneous NFs, and head circumference were previously reported in three large cohorts.^{6,7}

We investigated the genotype–phenotype association suggested by Pinna *et al* in our cohort of 219 genetically confirmed NF1 patients monitored at our Neurofibromatosis Referral Centre. We identified the c.5425C>T substitution in three unrelated probands, who were subsequently clinically re-examined together with their affected relatives. Our results fully replicated data by Pinna *et al*, and clinical features of affected individuals are summarized in Supplementary Table 1 (Family 1–3). Informed consent was obtained from all the subjects investigated. Mutation screening was carried out at the RNA level and completed by MLPA analysis.

We also speculated about the phenotypical impact of different changes in Arg¹⁸⁰⁹. We therefore looked for other missense variants affecting this position. Our cohort of genetically confirmed NF1 patients also included three related patients (Family 4) and one sporadic case (Family 5) carrying the already reported c.5426G>T p.(Arg1809Leu) substitution⁸ (Supplementary Table 1). In addition, a novel c.5426G>C p.(Arg1809Pro) substitution was present in a further sporadic case (Supplementary Table 1; Family 6). For sporadic patients, the *de novo* occurrence of NF1 was demonstrated by the exclusion of the mutation in children's parents. As with subjects carrying the p.(Arg1809Cys) substitution, those with a different amino

acid change at position 1809 also presented a mild NF1 phenotype with some NS features. These two variants were not annotated in the Exome Variant Server or in the ExAC Browser, which altogether collect data from about 68 000 human exomes. In addition, both amino acid changes were predicted to be deleterious by common *in silico* prediction programs (SIFT, Polyphen-2 and Mutation Taster), supporting their pathogenic effect.

In the patients presented here, and those described by Pinna *et al*, substitution of the charged and basic Arg¹⁸⁰⁹ with the hydrophilic Cys or the hydrophobic Leu and Pro amino acids seems to be always associated with a mild NF1 phenotype with only cutaneous pigmentary manifestations, without NFs and LNs, and with some NS features (Supplementary Table 1). Three-dimensional homology modeling,⁹ based on the available Sec/PH-like bipartite model (RCS-PDB: 2Q4D),¹⁰ confirmed that all the identified amino acid changes at position 1809 have the unique effect of removing the hydrogen bond between the side chain of Arg¹⁸⁰⁹ and the backbone of Ser¹⁷³⁸ (Supplementary Figure S1), as compared with the wild type (RefSeq: NP_000258.1; residues 1560–1816).

Our observations support the hypothesis that a rearrangement of the secondary structure of PH-like domain might modify the lipid-binding properties of the adjacent Sec14-like domain.^{1,10} However, it remains to be clarified why this change is not sufficient to cause typical NF1 signs (eg, LNs) and why it is associated with a reduced incidence of learning difficulties, whereas it is known that close to half of the children with NF1 experience variable cognitive vulnerability.^{11,12}

Five out of seven adults reported here showed at least one lipoma, suggesting that this mild NF1 phenotype might cause lipomas rather than NFs. Lipomas have been rarely reported in association with NF1^{13,14} and are frequent in the general population. Thus, their occurrence could be coincidental in these patients.

The lack of a clear genotype–phenotype correlation in NF1 is still considered to be a dogma by all clinicians involved in NF1 patient care. Our observations, however, together with those published by Pinna *et al*, further support a novel association between the Arg¹⁸⁰⁹ substitution and a mild NF1 phenotype, with a consequent impact on the prognosis, timing of follow-up, and genetic counseling.

For patients presenting with only multiple CALs, with or without SF, it may be worth prioritizing p.Met992del mutation and Arg¹⁸⁰⁹ substitution, when a *NF1* mutation screening is carried out. *NF1* testing should obviously be combined with *SPRED1* analysis.¹⁵

For such observational studies, sample sizes need to be scaled up owing to the relatively low frequency of the reported variants, likely underestimated as people with mild phenotypes might never require any medical assessment.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We are grateful to the patients and their families. We thank C Fischer for linguistic editing. CS, TG, and GP were supported in part by a grant from the NF1 Italian association (A.N.F. Onlus). GP was supported by a grant from Ministero dell'Istruzione dell'Università e della Ricerca (MIUR: PRIN 2010-11).

Claudia Santoro¹, Anna Maietta¹, Teresa Giugliano², Daniela Melis³, Silverio Perrotta¹, Vincenzo Nigro^{2,4} and Giulio Piluso^{*,2}
¹Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Seconda Università degli Studi di Napoli, Napoli, Italy;

²Dipartimento di Biochimica Biofisica e Patologia Generale, Seconda Università degli Studi di Napoli, Napoli, Italy;

³Dipartimento di Pediatria, Università degli Studi di Napoli "Federico II", Napoli, Italy;

⁴Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (NA), Italy
E-mail: giulio.piluso@unina2.it

- 1 Pinna V, Lanari V, Daniele P *et al*: p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. *Eur Hum Genet* 2015; **23**: 1068–1071.
- 2 Cawthon RM, Weiss R, Xu GF *et al*: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. *Cell* 1990; **62**: 193–201.
- 3 Kayes LM, Burke W *et al*: Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. *Am J Hum Genet* 1994; **54**: 424–436.
- 4 Pasmant E, Sabbagh A, Spurlock G *et al*: NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. *Hum Mutat* 2010; **31**: E1506–E1518.
- 5 Upadhyaya M, Huson SM, Davies M *et al*: An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. *Am J Hum Genet* 2007; **80**: 140–151.
- 6 Easton DF, Ponder MA, Huson SM, Ponder BA: An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. *Am J Hum Genet* 1993; **53**: 305–313.
- 7 Sabbagh A, Pasmant E, Laurendeau I *et al*: Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. *Hum Mol Genet* 2009; **18**: 2768–2778.
- 8 Griffiths S, Thompson P, Frayling I, Upadhyaya M: Molecular diagnosis of neurofibromatosis type 1: 2 years experience. *Fam Cancer* 2007; **6**: 21–34.
- 9 Biasini M, Bienert S, Waterhouse A *et al*: SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res* 2014; **42**: W252–W258.
- 10 D'Angelo I, Welti S, Bonneau F, Scheffzek K: A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. *EMBO Rep* 2006; **7**: 174–179.
- 11 Klein-Tasman BP, Janke KM, Luo W *et al*: Cognitive and psychosocial phenotype of young children with neurofibromatosis-1. *J Int Neuropsychol Soc* 2014; **20**: 88–98.
- 12 Payne JM, Hyman SL, Shores EA, North KN: Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. *Child Neuropsychol* 2011; **17**: 313–329.
- 13 Alkindy A, Chuzhanova N, Kini U, Cooper DN, Upadhyaya M: Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? *Hum Genomics* 2012; **6**: 12.
- 14 Oktenli C, Gul D, Deveci MS *et al*: Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. *Am J Med Genet A* 2004; **127A**: 298–301.
- 15 Stevenson D, Viskochil D, Mao R, Muram-Zborovski T: Legius Syndrome; in Pagon RA, Adam MP, Ardinger HH *et al*: (eds): *GeneReviews*. Seattle, WA, USA: University of Washington, 2010.

Supplementary Information accompanies this paper on *European Journal of Human Genetics* website (<http://www.nature.com/ejhg>)